UCART19
Phase 1Cell therapy
Institut de Recherches Internationales ServierUCART19 is one of 18 biologic programs targeting Lymphoid Leukemia. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Lymphoid Leukemia
#DrugCompanyPhaseTrials
1Arranon
NovartisApproved
Adriamycin
PfizerApproved
Cytosar
TevaApproved
Thalomid
Bristol-Myers SquibbApproved
Iclusig
TakedaApproved
Imbruvica
PPharmacyclics LLC.
Approved
Purinethol
SStason
Approved
Decadron
AAspen Global Incorporated
Approved
Coreg
Akero TherapeuticsApproved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia1 trial
Acute Lymphoblastic Leukaemia1 trial
Lymphoid Leukemia1 trial
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
Active, not recruiting·Institut de Recherches Internationales Servier·Phase 1·NCT02735083·28 enrolled
Institut de Recherches Internationales Servier·Phase 1·NCT02735083·28 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UCART19. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details